Nanoengineered sonosensitive platelets for synergistically augmented sonodynamic tumor therapy by glutamine deprivation and cascading thrombosis

Cancer Cell Membrane-Coated Nanoparticle Co-loaded with Photosensitizer and Toll-like Receptor 7 Agonist for the Enhancement of Combined Tumor Immunotherapy

“…In the process of antitumor immune response, APCs not only up-regulate costimulatory molecules on the surface but also regulate the function of other immune cells by secreting a series of pro-inflammatory cytokines, to mobilize the body’s immune system to produce a cascade reaction and initiate antitumor immune response, among which the typical pro-inflammatory cytokines are IL-6 and TNF. According to literature reports, − the pro-inflammatory factor IL-6 can promote the proliferation and differentiation of T cells into CTL cells and inhibit the differentiation of CD4 + T cells into immunosuppressive Treg cells and can promote B cells to secrete antibodies and other functions. TNF promotes the killing of tumor cells by T cells and other killer cells .…”

Self-Immolative Photosensitizers for Self-Reported Cancer Phototheranostics

“…However, the development of activatable photosensitizers requires a trigger that is significantly elevated in tumors. In tumor cells, the GSH level is significantly higher than the GSH level in normal cells, especially non-small-cell lung cancer, which can reach up to 10 mM. − Presumably, installation of the common 2,4-dinitrobenzenesulfonate trigger onto N1 afforded NG1 , which could distinguish GSH levels across lung cancer (Figure A). Unfortunately, NG1 displayed a good response to both GSH and cysteine (Figures S63 and S64).…”

Recent progress in metal–organic framework-based sonosensitizers for sonodynamic tumor therapy

“…This may be due to the complicated microenvironment in tumors, such as the heterogeneity of different tumor types, vascular system, and extracellular matrix in tumors that will impact on the therapeutic efficacy of ferroptosis in treatment. 108 For example, even with the same treatment, some types of tumors are sensitive to ferroptosis and can be effectively eliminated with fewer adverse effects, 109 while others may suffer unsatisfactory efficacy from ferroptosis therapy, sequentially leading to the risk of metastasis and recurrence. Therefore, from the perspective of ferroptosis, it is viable to increase the therapeutic efficacy by combining ferroptosis and other therapeutic modalities.…”